Bevacizumab for hereditary hemorrhagic telangiectasia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce bleeding in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of HHT, either through a clinical exam or a genetic test.
- Your nosebleeds must be severe enough that other treatments haven't worked well.
- You must be an adult (18 years or older).
- You must not have any medical condition that makes bevacizumab unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug Bevacizumab works and how safe it is for people with HHT who have severe liver problems that cause their heart to pump too much blood. It aims to help doctors understand if this treatment can help manage these serious symptoms.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
This trial tests a new topical gel (TOR-582) applied inside the nose to reduce nosebleeds in people with HHT. It may help by targeting the abnormal blood vessels that cause frequent bleeding.
Hear when a new Bevacizimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.